Drugs / MEDI-507
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06972069 | May 2025 → Dec 2030 expected | disease related to solid organ transplantation, kidney failure | Tatsuo Kawai, MD, PhD | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06326476 | May 2025 → Dec 2027 expected | hidradenitis suppurativa | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06455280 | Sep 2024 → Dec 2027 expected | autoimmune hepatitis, cirrhosis of liver, primary sclerosing cholangitis | Elizabeth C. Verna | Recruiting | No outcome recorded |
| Phase 1 | NCT01445535 | Jan 2009 → Apr 2011 | hepatosplenic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified, subcutaneous panniculitis-like T-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00105313 | Feb 2005 → ? | cancer, leukemia, lymphoma | MedImmune LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00123942 | Apr 2004 → ? | lymphoproliferative syndrome | MedImmune LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00063817 | Jun 2003 → Jan 2009 | end stage renal failure | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00813618 | Sep 1999 → Jun 2004 | acute graft versus host disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT00806728 | May → Nov 1998 | acute graft versus host disease, cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT00807794 | Feb → Nov 1997 | kidney disorder | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06078696 | Sep 2023 → Dec 2024 | sickle cell disease | Columbia University | Terminated | No outcome recorded |
| Phase 1/2 | NCT05574335 | Apr 2023 → May 2025 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT07508787 | Jun 2026 → Mar 2028 expected | transplant rejection | Nefro Avillion Clinical Development, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT00192452 | Mar → Dec 2001 | psoriasis | MedImmune LLC | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT04540380 Background | Sep 2021 → Jan 2029 expected | kidney failure | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00806208 Comparator | Jan 1999 → Jan 2000 | acute graft versus host disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT05900401 Background | Oct 2023 → Dec 2031 expected | kidney failure | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01780454 Background | Mar 2013 → Jun 2018 | end stage renal failure | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00801632 Background | Dec 2008 → Apr 2014 | chronic kidney disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00113646 Background | Nov 2002 → Dec 2007 | leukemia, myelodysplastic syndrome, plasma cell myeloma | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00540618 Comparator | Sep 2001 → Jul 2003 | psoriasis | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI-507 | “humanized anti-CD2 monoclonal antibody (MEDI-507)” NCT00063817 ↗ |
| Known as | Siplizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06455280 ↗ |
| Known as | TCD601 (Siplizumab) | “TCD601 (Siplizumab)” NCT06078696 ↗ |
| Action | Deplete | “a T-cell depleting antibody known as MEDI-507” NCT00063817 ↗ |
| Modality | Monoclonal antibody | “humanized anti-CD2 monoclonal antibody (MEDI-507)” NCT00063817 ↗ |
| Route | Intravenous | “Administered by Intravenous Infusion” NCT00192452 ↗ |
| Target | CD2 | “humanized anti-CD2 monoclonal antibody (MEDI-507)” NCT00063817 ↗ |